{"product_id":"mnmd-vrio-analysis","title":"Mind Medicine Inc. (MNMD): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Mind Medicine (MindMed) Inc. (MNMD) truly positioned for sustained success? This VRIO analysis cuts straight to the core, dissecting whether its key resources are Valuable, Rare, Inimitable, and Organized to create a lasting competitive edge. Discover the definitive assessment of Mind Medicine (MindMed) Inc. (MNMD)'s strategic foundation and what it means for their market dominance below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMind Medicine (MindMed) Inc. (MNMD) - VRIO Analysis: \u003cstrong\u003e1. MM120 ODT Phase 3 Clinical Data \u0026amp; Regulatory Status\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core asset driving Mind Medicine (MindMed) Inc.'s valuation right now: the late-stage clinical program for MM120 Orally Disintegrating Tablet (ODT). This is where the rubber meets the road for a pre-revenue biotech, and the near-term catalysts are all about hitting those Phase 3 data readouts.\u003c\/p\u003e\n\n\u003cp\u003eThe value proposition for MM120 is grounded in its Phase 2b success for Generalized Anxiety Disorder (GAD). That trial showed a single \u003cstrong\u003e100 µg\u003c\/strong\u003e dose led to a \u003cstrong\u003e48%\u003c\/strong\u003e remission rate at week 12, with a strong effect size of \u003cstrong\u003e0.81\u003c\/strong\u003e. Honestly, that effect size is more than double what we typically see with standard treatments like SSRIs (which show around 0.3).\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the current strategic setup:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n    \u003ctd\u003eAssessment\u003c\/td\u003e\n    \u003ctd\u003eKey Supporting Data (2025 Context)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003ePhase 2b GAD: \u003cstrong\u003e48%\u003c\/strong\u003e remission at Week 12; Effect Size \u003cstrong\u003e0.81\u003c\/strong\u003e\n\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eOne of the few psychedelic-inspired medicines in active Phase 3 for GAD\/MDD with published efficacy data\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eNo\u003c\/td\u003e\n    \u003ctd\u003eReplicating the specific clinical data package and securing FDA Breakthrough Therapy Designation for GAD is a high barrier\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eCash runway extends into 2028 post-offering; three pivotal trials actively enrolling\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eSustained (Conditional)\u003c\/td\u003e\n    \u003ctd\u003ePrimary asset driving future revenue potential, contingent on Phase 3 success\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe company is definitely organized around this asset. Mind Medicine (MindMed) Inc. is running three pivotal Phase 3 studies: Voyage (GAD), Panorama (GAD), and Emerge (MDD). They bolstered the balance sheet in October 2025 with a public offering netting approximately \u003cstrong\u003e$242.8 million\u003c\/strong\u003e, putting their cash reserves at \u003cstrong\u003e$209.1 million\u003c\/strong\u003e as of September 30, 2025, which management projects funds operations into 2028. This financial strength is crucial, given Q3 2025 R\u0026amp;D expenses surged to \u003cstrong\u003e$31.0 million\u003c\/strong\u003e, largely driven by the MM120 program.\u003c\/p\u003e\n\n\u003cp\u003eWhat this estimate hides is the execution risk. If onboarding for the trials slows, those anticipated 2026 readouts could slip. The regulatory pathway is also a moving target; while they have Breakthrough Therapy Designation for GAD, the MDD path relies on the Emerge and planned Ascend trial results.\u003c\/p\u003e\n\n\u003cp\u003eHere are the key timelines you need to track:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVoyage (GAD) topline data: Anticipated 1H 2026.\u003c\/li\u003e\n\u003cli\u003eEmerge (MDD) topline data: Accelerated to mid-2026.\u003c\/li\u003e\n\u003cli\u003ePanorama (GAD) topline data: Anticipated 2H 2026.\u003c\/li\u003e\n\u003cli\u003eMM402 Phase 2a study initiation: Expected by year-end 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe competitive advantage here is \u003cstrong\u003esustained\u003c\/strong\u003e only if they replicate the Phase 2b magnitude of effect in the Phase 3 setting, especially given the BTD for GAD.\u003c\/p\u003e\n\u003cp\u003eFinance: review the burn rate against the 2028 runway projection by next Tuesday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMind Medicine (MindMed) Inc. (MNMD) - VRIO Analysis: \u003cstrong\u003e2. Financial Liquidity and Runway Post-Financing\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e High. The cash position of \u003cstrong\u003e$209.1 million\u003c\/strong\u003e as of September 30, 2025, significantly bolstered by the \u003cstrong\u003e$242.8 million\u003c\/strong\u003e in net proceeds from the October 31, 2025 offering, provides runway into \u003cstrong\u003e2028\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e No. Many late-stage biotechs raise capital, but the timing and amount relative to their milestones is key.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e No. Competitors can raise capital, but this specific, secured runway is unique to their current structure.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. Management explicitly stated this funding strengthens their position for a transformational \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Liquidity is a necessary condition, but it's not a sustained advantage unless deployed perfectly.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents and Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$209.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Proceeds from Offering\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$242.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOctober 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Proceeds from Offering\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$258.9 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eOctober 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Funding Runway\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2028\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eBased on Sept 30, 2025 cash and net proceeds\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4.98\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest reported\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt-to-Equity Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.22\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest reported\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe financial strength is characterized by the following components:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents and investments totaled \u003cstrong\u003e$209.1 million\u003c\/strong\u003e as of September 30, 2025, compared to $273.7 million as of December 31, 2024.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe underwritten public offering on October 31, 2025, yielded estimated net proceeds of \u003cstrong\u003e$242.8 million\u003c\/strong\u003e after deducting underwriting discounts and commissions and other estimated offering expenses.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) expenses for the quarter ended September 30, 2025, were \u003cstrong\u003e$31.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe company intends to use net proceeds to fund R\u0026amp;D of product candidates, working capital, and general corporate purposes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eMind Medicine (MindMed) Inc. (MNMD) - VRIO Analysis: \u003cstrong\u003e3. MM120 ODT FDA Breakthrough Therapy Designation (GAD)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: High.\u003c\/strong\u003e This designation for Generalized Anxiety Disorder (GAD) streamlines regulatory review and signals strong initial FDA confidence in the data. The potential market includes approximately 20 million people in the U.S. living with GAD.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: Yes.\u003c\/strong\u003e This is a specific, high-value regulatory status granted only to promising candidates, announced in March 2024. The designation was supported by Phase 2b data showing rapid, robust, and durable activity through Week 12.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: No.\u003c\/strong\u003e It cannot be imitated; it must be earned through clinical demonstration. The underlying data supporting the designation is unique to MM120.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: Yes.\u003c\/strong\u003e The team is using this designation to inform their regulatory strategy for potential NDA filing, having reached alignment with the FDA on the Phase 3 development strategy following an End-of-Phase 2 meeting. The Phase 3 clinical program for MM120 ODT in GAD is on schedule to initiate in the second half of 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained.\u003c\/strong\u003e While the designation itself is a point-in-time achievement, the underlying data that earned it is a sustained advantage over competitors without it. The company reported a strong balance sheet with $252.3 million in cash and cash equivalents as of March 31, 2024, with a cash runway expected to fund operations into 2027 (as of March 31, 2025).\u003c\/p\u003e\n\u003cp\u003eThe clinical data supporting the Breakthrough Therapy Designation from the Phase 2b study (MMED008) are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eMM120 100 µg Cohort Data\u003c\/th\u003e\n\u003cth\u003eComparison\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStudy Population Baseline Severity (HAM-A)\u003c\/td\u003e\n\u003ctd\u003eAverage baseline score of approximately 30\u003c\/td\u003e\n\u003ctd\u003eIndicates moderate to severe GAD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Endpoint (HAM-A Change at Week 4)\u003c\/td\u003e\n\u003ctd\u003e-21.3 point reduction\u003c\/td\u003e\n\u003ctd\u003eCompared to -13.7 for placebo; p\u0026lt;0.0004\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Secondary Endpoint (HAM-A Change at Week 12)\u003c\/td\u003e\n\u003ctd\u003e7.7-point improvement over placebo\u003c\/td\u003e\n\u003ctd\u003eStatistically significant; p\u0026lt;0.003\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Response Rate (Week 12)\u003c\/td\u003e\n\u003ctd\u003e65%\u003c\/td\u003e\n\u003ctd\u003eDefined as at least a 50% improvement in HAM-A scores\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Remission Rate (Week 12)\u003c\/td\u003e\n\u003ctd\u003e48%\u003c\/td\u003e\n\u003ctd\u003eHAM-A score $\\le$7\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCGI-S Score Improvement (Week 12)\u003c\/td\u003e\n\u003ctd\u003eFrom 4.8 to 2.2\u003c\/td\u003e\n\u003ctd\u003eTwo-category shift from 'markedly ill' to 'borderline ill'\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe durability and breadth of the Phase 2b results informed the regulatory path:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eClinical activity was observed as early as 2 days post-treatment.\u003c\/li\u003e\n\u003cli\u003eThe 100 µg dose demonstrated optimal clinical activity.\u003c\/li\u003e\n\u003cli\u003eThe study supported the advancement of the MM120 oral dissolving tablet (ODT) formulation into pivotal trials.\u003c\/li\u003e\n\u003cli\u003eThe company plans to initiate Phase 3 trials, with topline data for the first GAD Phase 3 study (Voyage) anticipated in 1H 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eMind Medicine (MindMed) Inc. (MNMD) - VRIO Analysis: \u003cstrong\u003e4. MM402 (R(-)-MDMA) Pipeline Candidate for ASD\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Moderate\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdvancing MM402 into a Phase 2a study for Autism Spectrum Disorder (ASD) in \u003cstrong\u003eQ4 2025\u003c\/strong\u003e diversifies the pipeline beyond MM120.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003ePhase 2a study design: Single-dose, open-label.\u003c\/li\u003e\n\u003cli\u003eTarget enrollment: Up to \u003cstrong\u003e20\u003c\/strong\u003e adult participants.\u003c\/li\u003e\n\u003cli\u003ePrior milestone: Completed Phase 1 single-ascending dose study in adult healthy volunteers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: Yes\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe focus on the R(-)-enantiomer, suggesting potentially \u003cstrong\u003elower stimulant activity and neurotoxicity\u003c\/strong\u003e than racemic MDMA, is a specialized approach. Preclinical studies demonstrated \u003cstrong\u003ebetter efficacy\u003c\/strong\u003e than S(+)-MDMA or racemic MDMA in an animal model of ASD.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: Yes\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCompetitors can pursue similar enantiomers, but MindMed is first-mover in this specific trial initiation, with the Phase 2a study planned for \u003cstrong\u003eQ4 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: Yes\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThey are actively allocating R\u0026amp;D resources to this program, evidenced by financial reporting on program expenses.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2a Study Initiation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ4 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePlanned for ASD.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1 Study Status\u003c\/td\u003e\n\u003ctd\u003eCompleted\u003c\/td\u003e\n\u003ctd\u003eSingle-ascending dose in healthy volunteers.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMM402 Program R\u0026amp;D Expense Change\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eDecrease of $0.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 vs Q3 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMM402 Program R\u0026amp;D Expense Change\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eDecrease of $1.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 vs Q2 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMM402 Program R\u0026amp;D Expense Change\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eIncrease of $1.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2024 vs Q2 2023.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMM402 Program R\u0026amp;D Expense Change\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eDecrease of $0.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear ended 2023 vs 2022.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$209.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt offers a near-term advantage in pipeline diversification, but the space is competitive.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMind Medicine (MindMed) Inc. (MNMD) - VRIO Analysis: \u003cstrong\u003e5. Specialized Orally Disintegrating Tablet (ODT) Formulation\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: High.\u003c\/strong\u003e The ODT delivery method for MM120 is crucial for patient compliance and ease of administration, differentiating it from IV or capsule forms.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe 100 µg dose in Phase 2b GAD demonstrated a 7.7-point improvement over placebo on HAM-A at Week 12.\u003c\/li\u003e\n\u003cli\u003eThe 100-µg cohort in Phase 2b achieved a 48% clinical remission rate at Week 12.\u003c\/li\u003e\n\u003cli\u003eThe formulation incorporates Catalent's Zydis® ODT fast-dissolve technology.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: Yes.\u003c\/strong\u003e A proven, scalable ODT formulation for this class of compound is not common knowledge.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe U.S. Food \u0026amp; Drug Administration (FDA) granted MM120 for GAD Breakthrough Therapy Designation.\u003c\/li\u003e\n\u003cli\u003eThe U.K. MHRA granted an Innovation Passport for MM120 ODT under ILAP.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: No.\u003c\/strong\u003e Developing and validating a novel drug delivery system requires significant formulation science and regulatory navigation.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eStudy\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eTarget Enrollment\u003c\/th\u003e\n\u003cth\u003eDose Groups (MM120 ODT:Placebo)\u003c\/th\u003e\n\u003cth\u003eTopline Data Anticipated\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVoyage\u003c\/td\u003e\n\u003ctd\u003eGAD\u003c\/td\u003e\n\u003ctd\u003e$\\sim$200 participants\u003c\/td\u003e\n\u003ctd\u003e1:1 (100 µg)\u003c\/td\u003e\n\u003ctd\u003e1H 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePanorama\u003c\/td\u003e\n\u003ctd\u003eGAD\u003c\/td\u003e\n\u003ctd\u003e$\\sim$250 participants\u003c\/td\u003e\n\u003ctd\u003e2:1:2 (100 µg, 50 µg)\u003c\/td\u003e\n\u003ctd\u003e2H 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerge\u003c\/td\u003e\n\u003ctd\u003eMDD\u003c\/td\u003e\n\u003ctd\u003e$\\sim$140 participants\u003c\/td\u003e\n\u003ctd\u003e1:1 (100 µg)\u003c\/td\u003e\n\u003ctd\u003e2H 2026 (Anticipated mid-2026 as of 11\/2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: Yes.\u003c\/strong\u003e The entire late-stage program is built around this specific delivery mechanism.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) expenses related to the MM120 program were $9.4 million for Q1 2025.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D expenses for the MM120 program totaled $11.4 million for the full year 2024.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents were $273.7 million as of December 31, 2024, expected to fund operations into 2027.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained.\u003c\/strong\u003e Formulation IP and manufacturing know-how are hard to copy quickly.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNew patent (USPN 12,036,220) covers the pharmaceutical formulation and manufacturing methods for MM120 ODT.\u003c\/li\u003e\n\u003cli\u003eThe patent extends intellectual property protection for MM120 through 2041.\u003c\/li\u003e\n\u003cli\u003eMindMed holds exclusive rights to the Zydis technology for lysergide in the United States, the United Kingdom, the European Union, Switzerland, Israel, and Canada.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eMind Medicine (MindMed) Inc. (MNMD) - VRIO Analysis: \u003cstrong\u003e6. Executive Team with Commercial Readiness Focus\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Moderate.\u003c\/strong\u003e The appointment of Chief Commercial Officer (CCO) Matt Wiley on \u003cstrong\u003eMarch 17, 2025\u003c\/strong\u003e signals a strategic pivot toward market entry, supplementing clinical development success for MM120 ODT.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: No.\u003c\/strong\u003e The hiring of commercial leadership is standard for late-stage biotechs, but the specific timing relative to the anticipated 2026 Phase 3 readouts is a key strategic element.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: No.\u003c\/strong\u003e While specific deep experience in launching novel CNS\/psychiatric therapeutics is less common, executive talent is generally mobile and can be hired away, though the integration into the existing team structure is unique.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: Yes.\u003c\/strong\u003e The team structure is demonstrably evolving, evidenced by the CCO hire and the recent appointment of a new CFO, Brandi Roberts, effective June 2, 2025, indicating organizational alignment for the transition from clinical-stage to commercial-stage operations.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary.\u003c\/strong\u003e This capability is organizational and contingent upon successful execution of the commercial strategy post-potential FDA approval, which is not yet secured.\u003c\/p\u003e\n\u003cp\u003eThe strategic value of the executive team is underscored by the specific experience brought by Mr. Wiley, who possesses over 25 years of sales, marketing, and strategic leadership experience across multiple specialty product launches. This experience is directly relevant to the company's pipeline, which targets over 50 million people in the U.S. suffering from GAD or MDD.\u003c\/p\u003e\n\u003cp\u003eThe financial structure supports this commercial build-out:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003eContext\/Relevance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCCO Appointment Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMarch 17, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePrecedes anticipated 2026 Phase 3 data readouts.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWiley's Track Record\u003c\/td\u003e\n\u003ctd\u003eLed commercial strategy for XYREM® to blockbuster status\u003c\/td\u003e\n\u003ctd\u003eDemonstrated success in commercializing a novel CNS product.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (Pro-forma Post-Oct '25 Raise)\u003c\/td\u003e\n\u003ctd\u003eWell over \u003cstrong\u003e$450 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSufficient capital to fund operations into \u003cstrong\u003e2028\u003c\/strong\u003e, past key 2026 milestones.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 R\u0026amp;D Expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$31.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReflects high investment in advancing pivotal Phase 3 trials (Voyage, Panorama, Emerge).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInducement Award Value\u003c\/td\u003e\n\u003ctd\u003eOption for \u003cstrong\u003e350,000\u003c\/strong\u003e common shares and \u003cstrong\u003e125,000\u003c\/strong\u003e PSUs\u003c\/td\u003e\n\u003ctd\u003eDirect financial incentive tied to continued employment and performance.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe executive team's focus is on preparing for the potential launch of MM120 ODT, which has received Breakthrough Therapy Designation from the FDA for GAD. The company reported \u003cstrong\u003e$0.0 million\u003c\/strong\u003e in revenue for the third quarter of 2025, consistent with its pre-revenue, late-stage clinical status.\u003c\/p\u003e\n\u003cp\u003eKey aspects of the executive team's structure and focus include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCCO Matt Wiley's prior role overseeing the launch of the first acute treatment of agitation associated with schizophrenia and bipolar disorder at BioXcel Therapeutics.\u003c\/li\u003e\n\u003cli\u003eThe company's goal to advance MM120 ODT as a potential best-in-class therapeutic option for GAD and MDD.\u003c\/li\u003e\n\u003cli\u003eThe expectation of topline data from the Phase 3 Voyage trial in 1H 2026, followed by Panorama and Emerge in 2H 2026.\u003c\/li\u003e\n\u003cli\u003eThe cash balance as of June 30, 2025, was \u003cstrong\u003e$237.9 million\u003c\/strong\u003e, projected to fund operations into \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eMind Medicine (MindMed) Inc. (MNMD) - VRIO Analysis: \u003cstrong\u003e7. Intellectual Property via MindShift Compounds AG Partnership\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue: Moderate\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eThe ongoing development and patent filing for a portfolio of related compounds (phenethylamine, tryptamine, ergoline classes) builds a broader IP moat.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe partnership aims to discover pharmaceutically optimized research compounds and product candidates.\u003c\/li\u003e\n\u003cli\u003eMindMed planned to begin first-in-human Phase 1 clinical trials as early as \u003cstrong\u003eQ1 2022\u003c\/strong\u003e through its existing clinical trial platform for psychedelic and empathogenic compounds in Switzerland.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eRarity: Yes\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThis specific, long-standing partnership focused on optimizing these chemical classes is unique.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe partnership exclusively provides intellectual property related to new psychedelic compounds to MindMed.\u003c\/li\u003e\n\u003cli\u003eThe first initial compounds were synthesized by MindShift Compounds AG, and related patent applications were filed by MindMed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eImitability: No\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003ePatent thickets and exclusive development agreements are costly and time-intensive to replicate.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP Asset\/Activity\u003c\/td\u003e\n\u003ctd\u003eMetric\/Status\u003c\/td\u003e\n\u003ctd\u003eDate\/Period Reference\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSynthesis IP Ownership\u003c\/td\u003e\n\u003ctd\u003eOwned outright by MindMed\u003c\/td\u003e\n\u003ctd\u003ePartnership inception (February 11, 2021)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent Filings (Q2 2024)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e publications focused on European Patent Office (EPO)\u003c\/td\u003e\n\u003ctd\u003eQ2 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDominant Patent Office\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e~44%\u003c\/strong\u003e of filings concentrated in EPO\u003c\/td\u003e\n\u003ctd\u003eQ2 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$31.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarter ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization: Yes\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eDrug discovery and synthesis activities are ongoing, feeding the pipeline.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMindMed expects to continue to file a substantial number of patents on novel substance matters, production innovations, and later clinical applications.\u003c\/li\u003e\n\u003cli\u003eAll intellectual property and pharmaceutical technology related to the synthesis processes developed through the collaboration are owned outright by MindMed.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents and investments as of September 30, 2025, totaled \u003cstrong\u003e$209.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet proceeds from an offering completed October 31, 2025, were approximately \u003cstrong\u003e$242.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Sustained\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003ePatents provide the longest-lasting protection in pharma.\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eMindMed's Patent Filing Focus Regions (Q2 2024):\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEuropean Patent Office (EPO)\u003c\/li\u003e\n\u003cli\u003eUnited States (US)\u003c\/li\u003e\n\u003cli\u003eAustralia (AU)\u003c\/li\u003e\n\u003cli\u003eIsrael (IL)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eMind Medicine (MindMed) Inc. (MNMD) - VRIO Analysis: \u003cstrong\u003e8. Scientific Platform: Targeting Neurotransmitter Pathways\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Moderate.\u003c\/strong\u003e The foundational knowledge of targeting specific neurotransmitter pathways allows for rational drug design across multiple indications.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: Yes.\u003c\/strong\u003e While many biotechs do this, MindMed’s specific focus and experience in this novel area is specialized.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: Yes.\u003c\/strong\u003e Deep institutional knowledge and proprietary screening methods are difficult to copy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: Yes.\u003c\/strong\u003e This underpins their entire mission to develop novel product candidates.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained.\u003c\/strong\u003e A strong scientific platform is the bedrock of long-term R\u0026amp;D success.\u003c\/p\u003e\n\u003cp\u003eThe investment in this platform is reflected in Research and Development (R\u0026amp;D) expenditures, which were $65.3 million for the year ended December 31, 2024, compared to $52.1 million for the year ended December 31, 2023. Cash and cash equivalents as of December 31, 2024, totaled $273.7 million.\u003c\/p\u003e\n\u003cp\u003eThe platform's output is quantified through pipeline progression and formulation optimization:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eProgram\/Study\u003c\/th\u003e\n\u003cth\u003eValue\/Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDose Improvement (vs. Placebo)\u003c\/td\u003e\n\u003ctd\u003eMM120 100 µg in GAD Phase 2b (Week 12)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e7.7-point\u003c\/strong\u003e improvement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnset of Action\u003c\/td\u003e\n\u003ctd\u003eMM120 ODT vs. Non-ODT\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50% faster\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent Protection Extension\u003c\/td\u003e\n\u003ctd\u003eMM120 ODT Formulation\u003c\/td\u003e\n\u003ctd\u003eThrough 2041\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Status\u003c\/td\u003e\n\u003ctd\u003eMM120 for GAD\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFDA Breakthrough Therapy Designation\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 Enrollment Target\u003c\/td\u003e\n\u003ctd\u003eMM120 ODT Voyage (GAD)\u003c\/td\u003e\n\u003ctd\u003eApproximately 200 participants\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eProprietary technologies developed to optimize and personalize dosing regimens include patent applications for methods to screen and optimize the dosing of MDMA and LSD, developed with the University Hospital Basel.\u003c\/p\u003e\n\u003cp\u003eKey milestones directly enabled by the scientific platform:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInitiation of Phase 3 Voyage study of MM120 ODT in Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024.\u003c\/li\u003e\n\u003cli\u003eOn track to initiate Phase 3 Panorama study in GAD and Phase 3 Emerge study in Major Depressive Disorder (MDD) in the first half of 2025.\u003c\/li\u003e\n\u003cli\u003ePhase 3 Emerge study for MDD is expected to enroll 140 participants.\u003c\/li\u003e\n\u003cli\u003eTopline data anticipated in the first half of 2026 for Voyage (GAD) and the second half of 2026 for Panorama (GAD) and Emerge (MDD) (Part A results).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eMind Medicine (MindMed) Inc. (MNMD) - VRIO Analysis: \u003cstrong\u003e9. Disciplined Operational Execution in Phase 3 Enrollment\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: High\u003c\/strong\u003e. Maintaining strong enrollment momentum across all three pivotal trials demonstrates operational excellence and de-risks the 2026 data readouts.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: No\u003c\/strong\u003e. Many companies struggle with enrollment, but MindMed is hitting its targets.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Yes\u003c\/strong\u003e. It’s hard to copy the established site relationships and patient enthusiasm that drive fast enrollment.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Yes\u003c\/strong\u003e. The company is focused on disciplined execution to meet its timeline guidance.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary\u003c\/strong\u003e. Execution is excellent now, but any hiccup in site management could erode this advantage.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTrial\/Metric\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eEnrollment\/Target\u003c\/th\u003e\n\u003cth\u003eAnticipated Topline Readout\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVoyage (MM120-300)\u003c\/td\u003e\n\u003ctd\u003eGAD\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e200\u003c\/strong\u003e participants (U.S.)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1H 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePanorama (MM120-301)\u003c\/td\u003e\n\u003ctd\u003eGAD\u003c\/td\u003e\n\u003ctd\u003eDose-response arms\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2H 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerge (MM120-310)\u003c\/td\u003e\n\u003ctd\u003eMDD\u003c\/td\u003e\n\u003ctd\u003eAt least \u003cstrong\u003e140\u003c\/strong\u003e participants (randomized 1:1)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eMid-2026\u003c\/strong\u003e (Updated)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe operational execution is directly supported by significant financial resources secured through recent financing activities, which informs the cash flow outlook.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eCash, Cash Equivalents, and Investments as of September 30, 2025: \u003cstrong\u003e$209.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Proceeds from October 31, 2025, Public Offering: \u003cstrong\u003e$242.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePro-forma Cash Position (Post-Financing): Well over \u003cstrong\u003e$450 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eProjected Cash Runway: Sufficient to fund operations into \u003cstrong\u003e2028\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D Expenses for Q3 2025: \u003cstrong\u003e$31.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOperating Cash Flow (TTM ending Q3 2025): \u003cstrong\u003e-$113.94 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516209225877,"sku":"mnmd-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/mnmd-vrio-analysis.png?v=1740195648","url":"https:\/\/dcf-model.com\/pt\/products\/mnmd-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}